Skip to content

    Cipla

    CIPLANeutral
    Healthcare·30 Oct 2025
    Management Summary

    Cipla delivered exceptional Q2 FY26 performance with record quarterly revenue driven by growth across all priority markets - One India, US Generics, One Africa and EMEU. The quarter was marked by strategic milestones including the tirzepatide partnership with Eli Lilly and leadership succession planning with Achin Gupta's appointment as designated CEO.

    Highlights

    6

    • All-time high quarterly revenue of INR 7,589 crores with 8% YoY growth

    • Strong EBITDA margin of 25%

    • Tirzepatide partnership with Eli Lilly launched as 'Yurpeak'

    • Leadership transition announced - Achin Gupta to become CEO from April 2026

    • 29 brands now in INR 100+ crores club, added 4 new brands this quarter

    • US market share leadership in albuterol MDI at 22%

    Concerns

    1

    • Generic Revlimid Revenue Decline

    Key financials

    Single quarter

    08 metrics
    1. 01Total Revenue₹7,589 Cr+8%YoY
    2. 02EBITDA Margin25%0%YoY
    3. 03Profit After Tax₹1,351 Cr0%YoY
    4. 04R&D Investment₹539 Cr0%YoY
    5. 05Net Cash Balance₹9,901 Cr0%YoY

    Guidance & targets

    2
    CategoryTargetPriority
    FY26 EBITDA Margin
    EBITDA Margin
    22.75% to 24%
    		Medium
    US Business
    Revenue Target
    $1 billion
    		Medium

    Risks & concerns

    3
    RiskSeverity

    Generic Revlimid Revenue Decline

    Revlimid goes off patent in January 2026, Q3 expected to have minimal contribution — Other acknowledged

    high

    Increased R&D Spending

    R&D spend higher by 50 basis points due to additional programs and accelerated filings — Other acknowledged

    medium

    Regulatory Inspection Outcomes

    Bommasandra facility qualified as VAI, awaiting Indore facility reinspection — Other acknowledged

    medium

    Q&A highlights

    3

    “we don't manufacture API ourselves. We procure it and it is easily available in quantity. Fill and finish right now is through CMO”

    Clarifies manufacturing model for key growth product

    asked by Gautam R

    1 min read4 chapters

    Detailed Narrative

    01

    Record Financial Performance

    Cipla achieved all-time high quarterly revenue of INR 7,589 crores with 8% YoY growth, supported by robust 25% EBITDA margin. The performance was driven by balanced growth across all priority markets.

    02

    Strategic Partnership with Eli Lilly

    Launch of Yurpeak (tirzepatide) marks entry into obesity care segment. Partnership provides Cipla with nationwide distribution rights for first-and-only dual agonist GIP/GLP-1 receptor agonist.

    03

    Leadership Succession

    Achin Gupta appointed as designated CEO effective January 1, 2026, with full responsibilities from April 1, 2026. Brings over 20 years pharmaceutical experience and operational leadership.

    04

    US Market Leadership

    Emerged as number one player in US albuterol MDI market with 22% market share. Over 50 million inhalers supplied since launch. First biosimilar filgrastim launched in US market.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.